However, there is still approximately 40% of patients with migraine that have demonstrated an inadequate response to monoclonal antibodies and the gepants-targeting CGRP pathway, raising the question of CGRP as the sole or the main contributor to the peripheral mechanisms underlying migraine attacks [7]. This evidence concerns the gene CALCA and migraine disorder.